SLC38A2

Across TCGA pan-cancer cohorts, SLC38A2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC38A2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC38A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC38A2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where SLC38A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.236	0.753	<.001	52	view →
LUAD	OS	Tertile	II,III,IV	0.391	0.796	.005	14	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.892	.016	6	view →
CCRCC	OS	Tertile	III,IV	0.535	0.886	.048	5	view →
LSCC	DFS	Median	II,III,IV	0.988	0.848	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC38A2–PDAC (OS)

Open the PDAC breakdown →